Premium
Effect of granulocyte‐macrophage colony‐stimulating factor treatment on phenotype, cytokine release and cytotoxicity of circulating blood monocytes and monocyte‐derived macrophages
Author(s) -
B. Hennemann,
Marina Kreutz,
Annegret Rehm,
Reinhard Andreesen
Publication year - 1998
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1998.00922.x
Subject(s) - cd14 , tumor necrosis factor alpha , cytokine , monocyte , granulocyte macrophage colony stimulating factor , lipopolysaccharide , macrophage colony stimulating factor , cd16 , immunology , medicine , biology , cd163 , endocrinology , macrophage , flow cytometry , immune system , in vitro , cd8 , biochemistry , cd3
We studied phenotype, function and differentiation of mononuclear phagocytes in 11 cancer patients treated subcutaneously with 10 μg/kg recombinant human (rhu) GM‐CSF for 7 d. The rhuGM‐CSF treatment induced (1) a 5.9‐fold increase in the number of blood monocytes (MO), (2) a decrease of CD14 bright /CD16 bright cells with a diminution of the mean fluorescence intensity (MFI) of CD14, and (3) a decrease of MO cellular cytotoxicity. In patients' sera, tumour necrosis factor (TNF)‐α, interleukin (IL)‐10, IL‐12, neopterin, macrophage‐colony‐stimulating factor (M‐CSF), and IL‐1 receptor antagonist (IL‐1RA) increased, whereas GM‐CSF and granulocyte‐colony‐stimulating factor (G‐CSF) decreased after an initial peak. In whole blood samples the lipopolysaccharide (LPS)‐stimulated release of TNF‐α, IL‐6 and IL‐1RA increased initially, whereas IL‐1β, IL‐10 and IL‐12 decreased. During differentiation from MO to macrophages (MAC), interferon (IFN)‐γ‐stimulated tumour cytotoxicity increased, but both MO and MAC were less cytotoxic upon rhuGM‐CSF treatment. The differentiation‐associated increase of LPS‐induced TNF‐α, IL‐1RA and IL‐10 secretion was reduced by the rhuGM‐CSF treatment, and the expression of CD14 on MAC as well as the proportion of CD14 + /CD16 + , CD14 + /MAX.1 + and CD14 + /CD71 + cells in 7‐d cultured MAC declined. We interpret these findings as (1) an increase of immature MO upon rhuGM‐CSF therapy, (2) a priming effect on the LPS‐induced proinflammatory cytokine repertoire of MO, and (3) an impact of rhuGM‐CSF on the capacity of MO to differentiate to MAC in vitro .